Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-878271
KOS-1584 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm 25mg/m2 | EXPERIMENTAL | KOS-1584 25mg/m2 |
| Name | Type | Description |
|---|---|---|
| KOS-1584 | DRUG | 25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops. |
Inclusion Criteria: * Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV. * Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC. * Good performance status. Exclusion Criteria: * Prior treatment with an epothilone. * Known central nervo...
Top 20 of 90 competitors
KOS-1584 is an investigational small molecule being studied for the treatment of advanced or metastatic Stage IIIB/IV non-small cell lung cancer (NSCLC). It is being developed by Bristol-Myers Squibb Company. It has been evaluated in a Phase 2 study in patients with this condition, though it is not approved for any use.
KOS-1584 targets tubulin proteins, specifically TUBB4B, TUBB1, TUBA3C, TUBA4A, TUBB3, and TUBA1A. It acts as a tubulin stabiliser, meaning it binds to and stabilises microtubules, which are structural components essential for cell division. This mechanism interferes with the microtubule dynamics that cancer cells rely on to proliferate.
KOS-1584 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company sponsored the clinical evaluation of the drug in non-small cell lung cancer.
KOS-1584 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 trial evaluating it in non-small cell lung cancer has been completed.
KOS-1584 has been studied in one clinical trial, NCT00651508, titled "Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)." This Phase 2 trial was conducted in the United States, enrolled patients aged 18 years and older of all sexes, and has been completed.